-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
      name:  <unnamed>
       log:  /disk/homedirs/nber/bergerb/cortellis_projects/clinical_trials/reports/report_10-20-17/regs/regression_output_10-20-17.log
  log type:  text
 opened on:   1 Nov 2017, 14:31:34

. 
. 
. cap drop any_public*

. gen any_public = sponsor_public == 1 | collaborator_public == 1

. gen any_public_max = sponsor_public_max == 1 | collaborator_public_max == 1

. label variable any_public "Public firm (lower bound)"

. label variable any_public_max "Public firm (upper bound)"

. 
. * ------------------------------*
. * Main LPM regressions (Table 9)
. * ------------------------------*
. lpm_regs, lpm(g_lpm) estimator(regress) quietly 
Dependent variable: g_lpm

                    &       reg1a   &       reg1b   &       reg1c   &       reg1d   &       reg1e   &       reg1f   &       reg1g   &       reg1h   \\
                    &        b/se   &        b/se   &        b/se   &        b/se   &        b/se   &        b/se   &        b/se   &        b/se   \\
Trial start year    &      0.0038*  &      0.0038*  &      0.0038*  &      0.0038*  &      0.0050   &      0.0050   &      0.0050   &      0.0050   \\
                    &    (0.0014)   &    (0.0014)   &    (0.0014)   &    (0.0014)   &    (0.0024)   &    (0.0024)   &    (0.0024)   &    (0.0024)   \\
Phase 2 Clinical (includes Phase 2/Phase 3 trials)&      0.0097   &      0.0100   &      0.0097   &      0.0100   &      0.0124   &      0.0127   &      0.0129   &      0.0131   \\
                    &    (0.0095)   &    (0.0096)   &    (0.0093)   &    (0.0094)   &    (0.0109)   &    (0.0110)   &    (0.0107)   &    (0.0107)   \\
Phase 3 Clinical    &      0.0168   &      0.0166   &      0.0169   &      0.0167   &      0.0192   &      0.0189   &      0.0196   &      0.0193   \\
                    &    (0.0145)   &    (0.0145)   &    (0.0143)   &    (0.0143)   &    (0.0160)   &    (0.0159)   &    (0.0157)   &    (0.0157)   \\
Trial site in US=1  &      0.0126***&      0.0118***&      0.0120** &      0.0112** &      0.0132***&      0.0122***&      0.0087*  &      0.0078*  \\
                    &    (0.0020)   &    (0.0021)   &    (0.0032)   &    (0.0031)   &    (0.0026)   &    (0.0028)   &    (0.0035)   &    (0.0035)   \\
Drug indication for neoplasm=1&      0.1372***&      0.1373***&      0.1364***&      0.1365***&      0.1502***&      0.1502***&      0.1444***&      0.1444***\\
                    &    (0.0147)   &    (0.0147)   &    (0.0120)   &    (0.0120)   &    (0.0184)   &    (0.0184)   &    (0.0134)   &    (0.0133)   \\
NIH funding         &      0.0113   &      0.0128*  &      0.0111   &      0.0126*  &      0.0100   &      0.0114   &      0.0080   &      0.0095   \\
                    &    (0.0064)   &    (0.0060)   &    (0.0060)   &    (0.0056)   &    (0.0078)   &    (0.0071)   &    (0.0064)   &    (0.0058)   \\
Biomarker type: genomic=1&      0.2427*  &      0.2427*  &      0.2426*  &      0.2426*  &      0.2401*  &      0.2401*  &      0.2397*  &      0.2397*  \\
                    &    (0.1103)   &    (0.1102)   &    (0.1105)   &    (0.1104)   &    (0.1129)   &    (0.1128)   &    (0.1132)   &    (0.1131)   \\
Public firm (lower bound)&      0.0109*  &               &      0.0109*  &               &      0.0133*  &               &      0.0132*  &               \\
                    &    (0.0043)   &               &    (0.0043)   &               &    (0.0059)   &               &    (0.0060)   &               \\
Public firm (upper bound)&               &      0.0124*  &               &      0.0124*  &               &      0.0141*  &               &      0.0140*  \\
                    &               &    (0.0048)   &               &    (0.0048)   &               &    (0.0062)   &               &    (0.0062)   \\
Trial site in US=1 $\times$ Drug indication for neoplasm=1&               &               &      0.0017   &      0.0018   &               &               &      0.0137   &      0.0136  
>  \\
                    &               &               &    (0.0074)   &    (0.0074)   &               &               &    (0.0129)   &    (0.0130)   \\
Constant            &     -7.6809*  &     -7.7058*  &     -7.6846*  &     -7.7096*  &    -10.1021   &    -10.1975   &    -10.0812   &    -10.1759   \\
                    &    (2.8337)   &    (2.7885)   &    (2.8204)   &    (2.7752)   &    (4.8704)   &    (4.8595)   &    (4.8834)   &    (4.8735)   \\
N                   &      108749   &      108749   &      108749   &      108749   &       92568   &       92568   &       92568   &       92568   \\
r2                  &       0.271   &       0.271   &       0.271   &       0.271   &       0.279   &       0.279   &       0.279   &       0.279   \\
* p<0.05, ** p<0.01, *** p<0.001

. lpm_regs, lpm(r_lpm) estimator(regress) quietly
Dependent variable: r_lpm

                    &       reg1a   &       reg1b   &       reg1c   &       reg1d   &       reg1e   &       reg1f   &       reg1g   &       reg1h   \\
                    &        b/se   &        b/se   &        b/se   &        b/se   &        b/se   &        b/se   &        b/se   &        b/se   \\
Trial start year    &      0.0034*  &      0.0034*  &      0.0034*  &      0.0034*  &      0.0044   &      0.0044   &      0.0044   &      0.0044   \\
                    &    (0.0014)   &    (0.0013)   &    (0.0014)   &    (0.0013)   &    (0.0023)   &    (0.0023)   &    (0.0023)   &    (0.0023)   \\
Phase 2 Clinical (includes Phase 2/Phase 3 trials)&      0.0127   &      0.0131   &      0.0129   &      0.0132   &      0.0153   &      0.0156   &      0.0158   &      0.0162   \\
                    &    (0.0101)   &    (0.0101)   &    (0.0099)   &    (0.0100)   &    (0.0117)   &    (0.0117)   &    (0.0115)   &    (0.0115)   \\
Phase 3 Clinical    &      0.0215   &      0.0212   &      0.0217   &      0.0214   &      0.0236   &      0.0233   &      0.0241   &      0.0238   \\
                    &    (0.0153)   &    (0.0153)   &    (0.0152)   &    (0.0151)   &    (0.0170)   &    (0.0169)   &    (0.0168)   &    (0.0167)   \\
Trial site in US=1  &      0.0091***&      0.0081***&      0.0075** &      0.0065*  &      0.0090***&      0.0078***&      0.0035   &      0.0025   \\
                    &    (0.0014)   &    (0.0015)   &    (0.0024)   &    (0.0022)   &    (0.0017)   &    (0.0019)   &    (0.0024)   &    (0.0025)   \\
Drug indication for neoplasm=1&      0.1360***&      0.1362***&      0.1338***&      0.1340***&      0.1488***&      0.1488***&      0.1418***&      0.1418***\\
                    &    (0.0139)   &    (0.0139)   &    (0.0111)   &    (0.0111)   &    (0.0175)   &    (0.0175)   &    (0.0124)   &    (0.0124)   \\
NIH funding         &      0.0093   &      0.0111*  &      0.0088   &      0.0106   &      0.0100   &      0.0117*  &      0.0076   &      0.0094*  \\
                    &    (0.0056)   &    (0.0052)   &    (0.0054)   &    (0.0051)   &    (0.0059)   &    (0.0053)   &    (0.0050)   &    (0.0044)   \\
Biomarker type: genomic=1&      0.2174   &      0.2174   &      0.2173   &      0.2172   &      0.2142   &      0.2143   &      0.2137   &      0.2138   \\
                    &    (0.1086)   &    (0.1085)   &    (0.1087)   &    (0.1087)   &    (0.1110)   &    (0.1109)   &    (0.1112)   &    (0.1112)   \\
Public firm (lower bound)&      0.0138*  &               &      0.0138*  &               &      0.0163*  &               &      0.0162*  &               \\
                    &    (0.0054)   &               &    (0.0054)   &               &    (0.0071)   &               &    (0.0072)   &               \\
Public firm (upper bound)&               &      0.0154*  &               &      0.0154*  &               &      0.0171*  &               &      0.0170*  \\
                    &               &    (0.0057)   &               &    (0.0057)   &               &    (0.0073)   &               &    (0.0073)   \\
Trial site in US=1 $\times$ Drug indication for neoplasm=1&               &               &      0.0047   &      0.0048   &               &               &      0.0165   &      0.0164  
>  \\
                    &               &               &    (0.0069)   &    (0.0069)   &               &               &    (0.0123)   &    (0.0123)   \\
Constant            &     -6.8957*  &     -6.9257*  &     -6.9057*  &     -6.9359*  &     -8.8324   &     -8.9462   &     -8.8072   &     -8.9201   \\
                    &    (2.7655)   &    (2.7107)   &    (2.7552)   &    (2.7004)   &    (4.6835)   &    (4.6680)   &    (4.6941)   &    (4.6796)   \\
N                   &      108749   &      108749   &      108749   &      108749   &       92568   &       92568   &       92568   &       92568   \\
r2                  &       0.254   &       0.254   &       0.254   &       0.254   &       0.261   &       0.262   &       0.262   &       0.262   \\
* p<0.05, ** p<0.01, *** p<0.001

. 
. * ------------------------------*
. * Duration regressions (Table 10)
. * ------------------------------*
. duration_regs, end_dates("actual") quietly
(7,269 observations deleted)
actual
(65,275 observations deleted)
Printing Table 10a

                    &       reg1a   &       reg1b   &       reg1c   &       reg1d   &       reg1e   &       reg1f   \\
                    &        b/se   &        b/se   &        b/se   &        b/se   &        b/se   &        b/se   \\
Trial start year=2000&       0.000   &       0.000   &       0.000   &       0.000   &       0.000   &       0.000   \\
                    &         (.)   &         (.)   &         (.)   &         (.)   &         (.)   &         (.)   \\
Trial start year=2001&       5.246   &       5.604   &       6.280   &      -2.184   &      -2.004   &      -1.660   \\
                    &     (7.676)   &     (7.648)   &     (8.537)   &     (1.620)   &     (1.616)   &     (1.892)   \\
Trial start year=2002&      -5.741   &      -5.274   &      -4.558   &      -7.564***&      -7.059***&      -7.657***\\
                    &     (6.963)   &     (6.933)   &     (7.614)   &     (1.487)   &     (1.483)   &     (1.755)   \\
Trial start year=2003&     -11.702   &     -11.063   &      -9.411   &      -8.347***&      -7.749***&      -7.483***\\
                    &     (6.802)   &     (6.779)   &     (7.691)   &     (1.430)   &     (1.428)   &     (1.699)   \\
Trial start year=2004&     -11.468   &     -10.921   &      -7.878   &     -11.590***&     -11.023***&     -10.287***\\
                    &     (6.581)   &     (6.557)   &     (7.487)   &     (1.363)   &     (1.362)   &     (1.609)   \\
Trial start year=2005&     -16.409*  &     -15.412*  &     -15.178*  &     -14.439***&     -13.712***&     -13.358***\\
                    &     (6.447)   &     (6.437)   &     (7.284)   &     (1.333)   &     (1.332)   &     (1.561)   \\
Trial start year=2006&     -19.565** &     -18.710** &     -17.069*  &     -15.808***&     -15.102***&     -14.136***\\
                    &     (6.302)   &     (6.287)   &     (6.970)   &     (1.313)   &     (1.312)   &     (1.538)   \\
Trial start year=2007&     -17.563** &     -16.743** &     -16.965*  &     -18.277***&     -17.484***&     -17.261***\\
                    &     (6.162)   &     (6.145)   &     (6.771)   &     (1.301)   &     (1.300)   &     (1.519)   \\
Trial start year=2008&     -25.083***&     -24.152***&     -21.967** &     -19.016***&     -18.290***&     -18.208***\\
                    &     (6.144)   &     (6.131)   &     (6.779)   &     (1.294)   &     (1.294)   &     (1.509)   \\
Trial start year=2009&     -24.901***&     -23.863***&     -23.114***&     -20.337***&     -19.643***&     -20.086***\\
                    &     (6.058)   &     (6.042)   &     (6.674)   &     (1.288)   &     (1.287)   &     (1.500)   \\
Trial start year=2010&     -32.095***&     -31.016***&     -31.204***&     -21.635***&     -21.055***&     -21.137***\\
                    &     (6.049)   &     (6.037)   &     (6.678)   &     (1.285)   &     (1.284)   &     (1.496)   \\
Trial start year=2011&     -33.417***&     -32.343***&     -31.374***&     -23.355***&     -22.772***&     -23.139***\\
                    &     (5.989)   &     (5.974)   &     (6.574)   &     (1.279)   &     (1.279)   &     (1.485)   \\
Trial start year=2012&     -40.427***&     -39.318***&     -38.665***&     -24.579***&     -24.065***&     -24.297***\\
                    &     (5.985)   &     (5.971)   &     (6.572)   &     (1.278)   &     (1.277)   &     (1.487)   \\
Trial start year=2013&     -45.921***&     -44.999***&     -43.593***&     -26.468***&     -25.949***&     -26.979***\\
                    &     (5.985)   &     (5.965)   &     (6.574)   &     (1.275)   &     (1.274)   &     (1.478)   \\
Trial start year=2014&     -51.469***&     -50.183***&     -49.275***&     -29.506***&     -28.922***&     -30.167***\\
                    &     (5.982)   &     (5.974)   &     (6.572)   &     (1.271)   &     (1.271)   &     (1.469)   \\
Trial start year=2015&     -57.503***&     -56.163***&     -55.354***&     -32.818***&     -32.164***&     -34.076***\\
                    &     (6.003)   &     (5.998)   &     (6.617)   &     (1.271)   &     (1.271)   &     (1.472)   \\
Trial start year=2016&     -61.901***&     -60.343***&     -60.336***&     -34.992***&     -34.347***&     -36.524***\\
                    &     (6.308)   &     (6.341)   &     (7.048)   &     (1.279)   &     (1.280)   &     (1.490)   \\
Phase 2 Clinical (includes Phase 2/Phase 3 trials)&       2.028   &       2.063*  &       2.557   &       6.441***&       6.184***&       5.284***\\
                    &     (1.045)   &     (1.043)   &     (1.358)   &     (0.222)   &     (0.222)   &     (0.337)   \\
Phase 3 Clinical    &      14.164***&      14.367***&      13.400***&       9.262***&       9.374***&       7.095***\\
                    &     (1.564)   &     (1.554)   &     (2.063)   &     (0.253)   &     (0.252)   &     (0.397)   \\
Trial site in US    &       2.998** &       3.425***&               &       3.975***&       4.355***&               \\
                    &     (0.981)   &     (0.989)   &               &     (0.189)   &     (0.189)   &               \\
Drug indication for neoplasm&      12.930***&      13.038***&      12.391***&      19.387***&      19.214***&      18.171***\\
                    &     (1.282)   &     (1.275)   &     (1.755)   &     (0.269)   &     (0.268)   &     (0.374)   \\
Received NIH funding&       8.026***&       7.033** &       6.680** &      12.839***&      11.871***&      11.714***\\
                    &     (2.243)   &     (2.271)   &     (2.355)   &     (0.730)   &     (0.732)   &     (0.758)   \\
Public firm (lower bound)&      -2.608** &               &               &      -6.111***&               &               \\
                    &     (0.973)   &               &               &     (0.187)   &               &               \\
Public firm (upper bound)&               &      -4.308***&      -4.866***&               &      -7.238***&      -7.210***\\
                    &               &     (1.006)   &     (1.394)   &               &     (0.192)   &     (0.298)   \\
Constant            &      60.199***&      59.999***&      63.247***&      38.158***&      38.697***&      44.402***\\
                    &     (6.136)   &     (6.113)   &     (6.710)   &     (1.276)   &     (1.275)   &     (1.472)   \\
N                   &        2743   &        2743   &        1760   &       50186   &       50186   &       26101   \\
r2                  &       0.334   &       0.337   &       0.324   &       0.311   &       0.317   &       0.286   \\
* p<0.05, ** p<0.01, *** p<0.001
(43,741 observations deleted)
(0 real changes made)
Printing Table 10b

                    &       reg2a   &       reg2b   &       reg2c   &       reg2d   &       reg2e   &       reg2f   \\
                    &        b/se   &        b/se   &        b/se   &        b/se   &        b/se   &        b/se   \\
Trial start year=2000&       0.000   &       0.000   &       0.000   &       0.000   &       0.000   &       0.000   \\
                    &         (.)   &         (.)   &         (.)   &         (.)   &         (.)   &         (.)   \\
Trial start year=2001&       5.594   &       5.924   &       6.129   &       1.150   &       1.251   &       0.462   \\
                    &     (7.973)   &     (7.948)   &     (7.823)   &     (2.295)   &     (2.292)   &     (2.311)   \\
Trial start year=2002&      -2.413   &      -2.010   &      -2.315   &      -2.340   &      -2.081   &      -2.347   \\
                    &     (7.324)   &     (7.297)   &     (7.241)   &     (2.145)   &     (2.143)   &     (2.180)   \\
Trial start year=2003&     -10.265   &      -9.702   &     -11.321   &      -5.278*  &      -4.867*  &      -5.750** \\
                    &     (7.213)   &     (7.191)   &     (7.136)   &     (2.078)   &     (2.077)   &     (2.097)   \\
Trial start year=2004&      -7.502   &      -7.044   &      -7.672   &      -7.234***&      -6.769***&      -8.235***\\
                    &     (7.014)   &     (6.991)   &     (6.919)   &     (1.984)   &     (1.984)   &     (2.009)   \\
Trial start year=2005&     -13.101   &     -12.368   &     -13.496*  &     -10.498***&      -9.948***&     -11.344***\\
                    &     (6.870)   &     (6.859)   &     (6.741)   &     (1.915)   &     (1.917)   &     (1.942)   \\
Trial start year=2006&     -15.638*  &     -14.960*  &     -16.014*  &     -10.978***&     -10.401***&     -12.099***\\
                    &     (6.690)   &     (6.676)   &     (6.574)   &     (1.878)   &     (1.881)   &     (1.899)   \\
Trial start year=2007&     -13.507*  &     -12.819*  &     -14.181*  &     -15.273***&     -14.631***&     -16.419***\\
                    &     (6.543)   &     (6.528)   &     (6.449)   &     (1.853)   &     (1.857)   &     (1.880)   \\
Trial start year=2008&     -21.649***&     -20.857** &     -21.361***&     -16.137***&     -15.484***&     -17.357***\\
                    &     (6.525)   &     (6.516)   &     (6.431)   &     (1.852)   &     (1.854)   &     (1.879)   \\
Trial start year=2009&     -22.032***&     -21.121** &     -21.907***&     -18.546***&     -17.794***&     -19.907***\\
                    &     (6.439)   &     (6.426)   &     (6.350)   &     (1.829)   &     (1.833)   &     (1.864)   \\
Trial start year=2010&     -29.710***&     -28.833***&     -29.519***&     -21.756***&     -21.098***&     -23.508***\\
                    &     (6.437)   &     (6.427)   &     (6.359)   &     (1.832)   &     (1.834)   &     (1.864)   \\
Trial start year=2011&     -30.156***&     -29.240***&     -30.114***&     -25.801***&     -25.129***&     -27.625***\\
                    &     (6.364)   &     (6.350)   &     (6.274)   &     (1.820)   &     (1.823)   &     (1.863)   \\
Trial start year=2012&     -38.288***&     -37.369***&     -38.869***&     -29.086***&     -28.455***&     -30.982***\\
                    &     (6.364)   &     (6.352)   &     (6.279)   &     (1.828)   &     (1.830)   &     (1.870)   \\
Trial start year=2013&     -44.802***&     -43.994***&     -45.120***&     -32.992***&     -32.172***&     -35.273***\\
                    &     (6.367)   &     (6.349)   &     (6.266)   &     (1.820)   &     (1.821)   &     (1.858)   \\
Trial start year=2014&     -50.796***&     -49.757***&     -50.504***&     -40.118***&     -39.362***&     -41.264***\\
                    &     (6.362)   &     (6.354)   &     (6.272)   &     (1.817)   &     (1.819)   &     (1.855)   \\
Trial start year=2015&     -58.220***&     -57.014***&     -57.077***&     -46.983***&     -46.416***&     -47.759***\\
                    &     (6.403)   &     (6.410)   &     (6.324)   &     (1.823)   &     (1.822)   &     (1.869)   \\
Trial start year=2016&     -65.084***&     -63.855***&     -65.572***&     -49.946***&     -49.878***&     -51.856***\\
                    &     (6.520)   &     (6.541)   &     (6.480)   &     (1.881)   &     (1.882)   &     (1.894)   \\
Phase 2 Clinical (includes Phase 2/Phase 3 trials)&       1.619   &       1.626   &       1.611   &       3.106***&       3.045***&       2.977***\\
                    &     (1.126)   &     (1.124)   &     (1.138)   &     (0.483)   &     (0.482)   &     (0.516)   \\
Phase 3 Clinical    &      16.378***&      16.478***&      16.216***&      13.128***&      13.043***&      12.888***\\
                    &     (1.884)   &     (1.875)   &     (1.877)   &     (0.932)   &     (0.928)   &     (0.983)   \\
Trial site in US    &       3.062** &       3.404** &       3.566** &       3.207***&       3.497***&       2.545***\\
                    &     (1.095)   &     (1.106)   &     (1.103)   &     (0.481)   &     (0.482)   &     (0.514)   \\
Received NIH funding&       8.011***&       7.172** &       7.157** &       8.347***&       7.721***&       6.633***\\
                    &     (2.342)   &     (2.376)   &     (2.361)   &     (1.113)   &     (1.126)   &     (1.190)   \\
Public firm (lower bound)&      -2.162*  &               &               &      -5.506***&               &               \\
                    &     (1.081)   &               &               &     (0.473)   &               &               \\
Public firm (upper bound)&               &      -3.551** &      -3.945***&               &      -6.032***&      -6.386***\\
                    &               &     (1.117)   &     (1.123)   &               &     (0.470)   &     (0.496)   \\
Biomarker role (detailed): diagnosis&               &               &      -1.457   &               &               &       2.181   \\
                    &               &               &     (3.112)   &               &               &     (1.333)   \\
Biomarker role (detailed): differential diagnosis&               &               &       6.618***&               &               &       2.881*  \\
                    &               &               &     (1.543)   &               &               &     (1.203)   \\
Biomarker role (detailed): predicting drug resistance&               &               &       0.051   &               &               &      -1.945   \\
                    &               &               &     (1.410)   &               &               &     (1.637)   \\
Biomarker role (detailed): predicting treatment efficacy&               &               &      -1.345   &               &               &       4.412***\\
                    &               &               &     (3.335)   &               &               &     (1.280)   \\
Biomarker role (detailed): predicting treatment toxicity&               &               &      -3.127   &               &               &       0.201   \\
                    &               &               &     (2.290)   &               &               &     (2.009)   \\
Biomarker role (detailed): screening&               &               &       0.542   &               &               &       1.996   \\
                    &               &               &     (1.637)   &               &               &     (2.153)   \\
Biomarker role (detailed): selection for therapy&               &               &       3.342*  &               &               &      -0.743   \\
                    &               &               &     (1.438)   &               &               &     (1.545)   \\
Biomarker role (detailed): disease profiling&               &               &       2.895   &               &               &       0.485   \\
                    &               &               &     (1.623)   &               &               &     (1.093)   \\
Biomarker role (detailed): monitoring disease progression&               &               &      -3.938*  &               &               &      -1.326   \\
                    &               &               &     (1.723)   &               &               &     (1.707)   \\
Biomarker role (detailed): monitoring treatment efficacy&               &               &       1.605   &               &               &       1.853   \\
                    &               &               &     (1.842)   &               &               &     (1.173)   \\
Biomarker role (detailed): monitoring treatment toxicity&               &               &      -7.723*  &               &               &       2.060   \\
                    &               &               &     (3.061)   &               &               &     (2.787)   \\
Biomarker role (detailed): not determined&               &               &      -3.043   &               &               &      -4.144   \\
                    &               &               &     (2.232)   &               &               &     (3.684)   \\
Biomarker role (detailed): prognosis&               &               &       0.299   &               &               &      -0.674   \\
                    &               &               &     (2.166)   &               &               &     (1.296)   \\
Biomarker role (detailed): prognosis - risk stratification&               &               &       1.246   &               &               &      -3.498   \\
                    &               &               &     (1.697)   &               &               &     (2.128)   \\
Biomarker role (detailed): risk factor&               &               &      -1.954   &               &               &      -0.637   \\
                    &               &               &     (2.019)   &               &               &     (1.118)   \\
Biomarker role (detailed): staging&               &               &      -2.763   &               &               &      -3.552** \\
                    &               &               &     (1.563)   &               &               &     (1.373)   \\
Biomarker role (detailed): toxicity profiling&               &               &       0.000   &               &               &       6.110   \\
                    &               &               &         (.)   &               &               &     (8.979)   \\
Constant            &      70.225***&      70.159***&      69.232***&      58.019***&      58.086***&      58.443***\\
                    &     (6.410)   &     (6.384)   &     (7.728)   &     (1.785)   &     (1.786)   &     (1.808)   \\
N                   &        2289   &        2289   &        2289   &       12423   &       12423   &       11052   \\
r2                  &       0.308   &       0.310   &       0.324   &       0.197   &       0.199   &       0.208   \\
* p<0.05, ** p<0.01, *** p<0.001

. 
. 
. 
. 
. /*
> * ------------------------------*
> * Appendix reg table: (Table A11)
> * ------------------------------*
> lpm_regs, lpm(g_lpm) estimator(logit) margins quietly
> lpm_regs, lpm(r_lpm) estimator(logit) margins quietly
> */
. 
. 
. 
. log close
      name:  <unnamed>
       log:  /disk/homedirs/nber/bergerb/cortellis_projects/clinical_trials/reports/report_10-20-17/regs/regression_output_10-20-17.log
  log type:  text
 closed on:   1 Nov 2017, 14:31:58
-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
